¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"calcium channel agonist"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® agonist ÇÑ±Û ÀÛ¿ëÁ¦, ÀÛ¿ë±Ù
¼³¸í   
  1. ¼ö¿ëü¿Í °áÇÕÇÏ¿© ÃÖ´ëÀÇ ¾à¸®ÀÛ¿ëÀ» ¹ßÇöÇϴ ȭÇй°ÁúÀ» ¸»ÇÑ´Ù. ¼ö¿ëü¿¡ Æ¯ÀÌÇϰԠģȭ¼ºÀ» °¡Áö°í ÀÖ´Ù. »ýü ¾È¿¡¼­ »ý»êµÇ´Â ³»ÀμºÀΠ°Í°ú »ýü ¹Û¿¡¼­ Åõ¿©µÇ´Â ¿ÜÀμºÀΠ°ÍÀÌ ÀÖ´Ù. ºÎºÐ ÀÛ¿ëÁ¦´Â ¼ö¿ëü¿Í °áÇÕÇØµµ 100%ÀÇ ¾à¸®ÀÛ¿ëÀ» ¹ßÇöÇÏÁö´Â ¾ÊÀ¸¸ç ¿ë·®À» Áõ°¡½ÃÄѵµ È¿°ú´Â Ä¿ÁöÁö ¾Ê´Â´Ù. 2. ÇغÎÇп¡¼­´Â ÁÖ°¡ µÇ¾î ¿òÁ÷À̴ ±ÙÀ°ÀÇ ¹«¸®
  
  
¿µ¹® calcium ÇÑ±Û Ä®½·
¼³¸í   
  ½ÅüÀÇ °ÅÀÇ ¸ðµç Á¶Á÷¿¡¼­ ¹ß°ßµÇ´Â ÀüÇØÁú·Î ¿©·¯ °¡Áö ¿ªÇÒÀ» ¸ö¿¡¼­ ´ã´çÇÑ´Ù. Áß¿äÇÑ ±â´ÉÀ» »ìÆìº¸¸é ¿ì¼± Àλê°ú °áÇÕÇÏ¿© »À³ª ÀÌ»¡À» ¸¸µå´Â ¿ªÇÒÀ» ÇÑ´Ù. ±×¸®°í ¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡ ¾ø¾î¼­´Â ¾ÈµÉ ÀüÇØÁú·Î ÀÛ¿ëÀ» ÇÑ´Ù. Ç÷¾×ÀÀ°íÀÇ ¿©·¯ ´Ü°è¿¡µµ °ü¿©ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • calcium-channel blocker
    Ä®½·Åë·ÎÂ÷´ÜÁ¦
  • agonist
    1. ÀÛ¿ëÁ¦ 2. ÀÛ¿ë±Ù
  • beta2-agonist
    º£Å¸2ÀÛ¿ëÁ¦
  • cholinergic agonist
    Äݸ°¼ºÀÛ¿ëÁ¦
  • dopamine agonist
    µµÆÄ¹ÎÀÛ¿ëÁ¦
  • GnRH agonist
    »ý½Ä»ùÀÚ±ØÈ£¸£¸ó¹æÃâÈ£¸£¸óÀÛ¿ëÁ¦
  • gonadotropin-releasing hormone agonist
    »ý½Ä»ùÀÚ±ØÈ£¸£¸ó¹æÃâÈ£¸£¸óÀÛ¿ëÁ¦
  • inverse agonist
    ¿ªÀÛ¿ëÁ¦
  • muscarinic agonist
    ¹«½ºÄ«¸°ÀÛ¿ëÁ¦
  • opioid agonist
    ¾ÆÆíÀ¯»çÀÛ¿ëÁ¦
  • coronary calcium scan
    °ü»óµ¿¸ÆÄ®½·½ºÄµ
  • calcium
    Ä®½·
  • calcium chloride
    ¿°È­Ä®½·
  • calcium ethylenediaminetetraacetic acid
    Ä®½·¿¡Æ¿·»µð¾Æ¹Î»ç¾Æ¼¼Æ®»ê
  • calcium gluconate
    ±Û·çÄÜ»êÄ®½·
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gonadotropin releasing hormone agonist agonist
    »ý½Ä»ùÀÚ±ØÈ£¸£¸óºÐºñÈ£¸£¸óÀÛ¿ëÁ¦
  • channel
    Åë·Î
  • sodium channel
    ³ªÆ®·ýÅë·Î
  • calcium ethylenediaminetetraacetic acid
    Ä®½·¿¡Æ¿·»µð¾Æ¹Î»ç¾Æ¼¼Æ®»ê
  • calcium
    Ä®½·
  • calcium gluconate
    ±Û·çÄÜ»êÄ®½·
  • agonist
    1.ÀÛ¿ëÁ¦, 2.ÀÛ¿ë±Ù
  • beta2 agonist
    º£Å¸2ÀÛ¿ëÁ¦
  • dopamine agonist
    µµÆÄ¹ÎÀÛ¿ëÁ¦
  • GnRH agonist
    (¢¡gonadotropin releasing hormone agonist) »ý½Ä»ùÀÚ±ØÈ£¸£¸óºÐºñÈ£¸£¸óÀÛ¿ëÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agonist
    ÀÛ¿ëÁ¦, ÀÛ¿ë±Ù
  • cholinergic agonist
    Äݸ°¼ºÃËÁøÁ¦
  • inverse agonist
    ¿ªÀÛ¿ëÁ¦
  • muscarinic agonist
    ¹«½ºÄ«¸°ÀÛ¿ëÁ¦
  • opioid agonist
    ¾ÆÆíÀ¯»çÀÛ¿ëÁ¦
  • calcium
    Ä®½·
  • calcium chloride
    ¿°È­Ä®½·
  • calcium oxalate stone
    ¼ö»êÄ®½·µ¹
  • calcium phosphate stone
    ÀλêÄ®½·µ¹
  • calcium-catalyzed reaction
    Ä®½·Ã˸ŹÝÀÀ
  • channel block
    Åë·ÎÂ÷´Ü
  • channel
    Åë·Î
  • cation channel
    ¾çÀÌ¿ÂÅë·Î
  • collateral channel
    °çÅë·Î
  • collector channel
    Áý°á°ü, Áý°á·Î
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • GnRH agonist
    ¼º¼±ÀÚ±ØÈ£¸£¸ó À¯¸® È£¸£¸ó È¿´É¾à
  • alpha-adrenergic agonist
    ¾ËÆÄ¾Æµå·¹³¯¸°ÃËÁøÁ¦
  • Fast channel
    ±Þ¼Ó(ÐááÜ)Åë·Î(÷×ÖØ)
  • T-type channel
    T-Çü Åë·Î
  • acetylcholine channel
    ¾Æ¼¼Æ¿Äݸ° Åë·Î
  • hepatocardiac channel
    °£½ÉÀå__ÊÜãýíôϵ).
  • porin channel
    Æ÷¸°Åë·Î
  • potassium channel
    Ä®·ýÅë·Î
  • pyloric channel
    À¯¹®Åë·Î.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à ¹°<Á¦>, Ä®½·Åë·Î Â÷´Ü¾à¹°<Á¦>.
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à¹°<Á¦>, Ä®½·Åë·ÎÂ÷´Ü¾à¹°<Á¦>.
  • calcium channel
    Ä®½·Åë·Î( -÷×ÖØ).
  • calcium channel
    Ä®½· Åë·Î(÷×ÖØ)
  • calcium channel antagonist,blocker
    Ä®½·Åë·Î ±æÇ×Á¦( -÷×ÖØ ÑÏù÷ð¥),Â÷´ÜÁ¦(ó´Ó¨ð¥).
  • adrenergic agonist
    ¾Æµå·¹³¯¸°¼ºÃËÁøÁ¦
  • agonist
    ÀÛ¿ëÁ¦(íÂéÄð¥), ÈïºÐÁ¦(ýéÝÇð¥)
  • agonist
    È¿´É¾à(üùÒöå·), È¿ÇöÁ¦(üùúéð¥).
  • alpha-adrenergic agonist
    ¾ËÆÄ¾Æµå·¹³¯¸°ÃËÁøÁ¦
  • cholinergic agonist
    Äݸ°¼º ÃËÁøÁ¦
  • dopamine agonist
    µµÆÄ¹Î È¿ÇöÁ¦(üùúÞð¥)
  • dopamine autoreceptor agonist
    µµÆÄ¹Î ÀÚ°¡¼ö¿ëü È¿ÇöÁ¦
  • inverse agonist
    ¿ª(¼º)È¿Çö<´É>Á¦.
  • muscarinic agonist
    ¹«½ºÄ«¸°¼ºÀÛ¿ëÁ¦
  • opioid agonist
    ¾ÆÆí¾çÀÛ¿ëÁ¦
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • calcium folinate
    Ä®½·Æú¸®³×ÀÌÆ®
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agonist
    ÀÛµ¿Ã¼ (íÂÔÑô÷)
  • cholinergic agonist
    Äݸ°ÀÛµ¿Á¦(íÂÔÑð¥)
  • partial agonist
    ºÎºÐ ÀÛµ¿Á¦(Ý»ÝÂíÂÔÑð¥)
  • channel
    "ä³Î, Åë·Î(÷×ÖØ)"
  • channel protein
    ä³Î ´Ü¹éÁú(Ó±ÛÜòõ)
  • gated channel
    °ü¹® Åë·Î (μڦ÷×ÖØ)
  • ion channel
    À̿ Åë·Î(÷×ÖØ)
  • ligand-gated channel
    ¸®°£µå °ü¹®Åë·Î(μڦ÷×ÖØ)
  • voltage-gated channel
    Àü¾Ð°³Æó(ï³äâËÒøÍ) Åë·Î(÷×ÖØ)
  • calcium
    Ä®½·
  • calcium-activated factor
    Ä®½·ºÎȰ ÀÎÀÚ(Ý·üÀì×í­)
  • calcium-activated neutral proteinase
    Ä®½·ºÎȰ(Ý·üÀ) Áß¼º(ñéàõ)ÇÁ·ÎƼ³×À̽º
  • calcium chloride transformation
    ¿°È­Ä®½· º¯Çü¼ú(ܨû¡âú)
  • calcium-dependent proteinase
    Ä®½·ÀÇÁ¸(ëîðí) ÇÁ·ÎƼ³×À̽º
  • calcium-dependent regulatory protein
    Ä®½·ÀÇÁ¸ Á¶Àý´Ü¹éÁú(ëîðíðàï½Ó±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • calcium
    Ä®½·
  • calcium, milk
    Ä®½·¿ìÀ¯
  • milk of calcium
    ¿ìÀ¯ÇüÄ®½·
  • milk of calcium bile
    ¿ìÀ¯ÇüÄ®½·´ãÁó
  • channel
    Åë·Î
  • collateral channel
    °çÅë·Î, ºÎÇà·Î
  • hepatocardiac channel
    °£½ÉÀ屸
  • lymph channel
    ¸²ÇÁ°ü
  • parallel channel sign
    ÆòÇà°ü¡ÈÄ
  • signal channel
    ½ÅÈ£Åë·Î
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Ca2+-blocker calcium channel blocker
CCB calcium channel blocker
DHPCCB dihydropyridine calcium channel blocker
NDHPCCB non-dihydropyridine calcium channel blocker
TC target cell; taurocholate; temperature compensation; teratocarcinoma; tertiary cleavage; tetracyclin...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
KATP channel ATP sensitive potassium channel
BK channel K channel
CRC Calcium Release Channel
CCA Calcium channel antagonists
CCB Calcium channel blocker
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • channel tray ºÐÇÒ º¹À§½Ä ¸ðÇüÀ» Á¦ÀÛÇÒ ¶§ »ç¿ëµÇ´Â ÇÃ¶ó½ºÆ½ ʹÝ. Dilok tray¿Í °°Àº ±â´ÉÀ» ÇÏ´Â °ÍÀÌ´Ù.

    channel-shoulder-pin attachment

    ¾¾ ¿¡½º ÇÇ ºÎ°¡ ÀåÄ¡
    Ä¡°ú ±â°ø½Ç¿¡¼­ Á¦ÀÛÇÒ ¼ö ÀÖ´Â °ÍÀ¸·Î °¢Á¾ Àΰø Ä¡°ú
  • calcium channel
    Ä®½· ä³Î
    Ä®½·ÀÌ Åë°úÇÏ´Â µµ°ü.
  • calcium channel blocker
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°, Ä®½· ä³Î Â÷´ÜÁ¦
    µ¿ÀǾî=calcium channel blocking drug. 1. Ä®½·ÀÌ Åë°úÇÏ ´Â µµ°üÀ» ¸·´Â ¾à¹°. 2. Ç× Çù½ÉÁõ Á¦Á¦, Ç×°íÇ÷¾Ð Á¦Á¦, Ç× ºÎÁ¤¸Æ Á¦Á¦·Î »ç¿ëµÇ´Â ¾à¹°·Î½á, µ¿¸ÆÀÇ ÆòȰ±Ù¿¡¼­ Ä®½·ÀÇ À¯ÀÔÀ» Â÷´ÜÇÔÀ¸·Î½á ¸»ÃÊ ¼Òµ¿¸ÆÀ» ÀÌ¿ÏÇØ¼­ ½É±ÙÀÇ »ê¼Ò ¿ä±¸·®À» ÀúÇϽÃŰ´Â ±â´ÉÀ» ÇÑ´Ù. ´ëÇ¥ÀûÀÎ ¾à¹°·Î´Â, vera
  • calcium channel blocking drug
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°
  • calcium-channel blocker
    Ä®½· Â÷´ÜÁ¦, Ä®½· Åë·Î Â÷´ÜÁ¦
  • 2-adrenergic agonist
    2-¾Æµå·¹³¯¸° ÀÛ¿ëÁ¦, 2-¾Æµå·¹³¯¸° ÀÛµ¿Á¦
  • adrenergic agonist
    ¾Æµå·¹³¯¸°¼º ÀÛµ¿¾à
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü¸¦ ÈïºÐ½ÃÅ´À¸·Î½á È¿°ú¸¦ ³ªÅ¸³»´Â ¾à¹°. ´ë°Ô ¾Æ¹Î È­ÇÕ¹°À̹ǷΠ±³°¨½Å°æ À¯»ç ¾Æ¹ÎÀ̶ó°íµµ ÇÑ´Ù.
  • agonist muscle
    µ¿±Ù±º, ÁÖµ¿±Ù
  • alpha 2 agonist clonidine
    ¾ËÆÄ 2 ÀÛµ¿ Ŭ·Î´Ïµò
  • dopamine autoreceptor agonist
    µµÆÄ¹Î ÀÚ°¡ ¼ö¿ëü È¿ÇöÁ¦
  • high-affinity agonist
    °íģȭ¼º ÀÛ¿ë ¹°Áú
  • opiate agonist alkaloid
    ¾ÆÆí¼º ÀÛµ¿ ¹°Áú ¾ËÄ«·ÎÀ̵å
  • channel block
    Åë·Î Â÷´Ü
  • collateral channel
    °çÅë·Î, ºÎÇà·Î
  • ion channel
    À̿ Åë·Î
    ¼¼Æ÷¸· µî¿¡ Á¸ÀçÇϸç ÀÚ±ØÀÌ ¿À¸é Åë·Î¸¦ ¿­°í, ´ÝÀ½À¸·Î ÇØ¼­ ÀÌ¿ÂÀÇ ³óµµ¸¦ Á¶ÀýÇØ¼­ ÀÚ±ØÀÇ Àü´Þ¿¡ °ü¿©ÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
calcium channel agonist <pharmacology> Agents that increase calcium influx into calcium channels of excitable tissues.
This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
calcium channel <physiology> A membrane channel that is specific for calcium. It is a voltage-dependent cell membrane glycoproteins selectively permeable to calcium ions. They are categorised as l, t, n, or p types based on the activation and inactivation kinetics, ion specificity, and sensitivity to drugs and toxins.
(12 May 2002)
calcium channel antagonist <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
calcium channel-blocker <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
ryanodine receptor calcium release channel Protein complexes that mediate the release of calcium from the sarcoplasmic reticulum in both skeletal and cardiac muscle cells by forming tetrametric complexes. These complexes each then act as a calcium channel. There are three isoforms of the ryr: ryr1, ryr2, and ryr3. Ryr1 is specifically expressed in skeletal muscles and ryr2 in cardiac muscles. Ryr3 is yet another isoform found in non-muscle cells such as neuronal cells.
(12 Dec 1998)
agonist 1. <anatomy> A prime mover.
2. <pharmacology> A drug that has affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances, thus triggering a biochemical response.
(18 Nov 1997)
receptor agonist A substance that mimics a specificneurotransmitter, is able to attach to that neurotransmitter's receptor and thereby produces the same action that theneurotransmitter usually produces. Drugs are often designed as receptor agonists to treat a variety of diseases and disorders whenthe original chemical substance is missing or depleted.
(22 May 1997)
mixed opioid agonist-antagonist <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type.
(13 Nov 1997)
muscarinic agonist Drugs that bind to and activate muscarinic cholinergic receptors (receptors, muscarinic). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate.
(12 Dec 1998)
histamine agonist Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically.
(12 Dec 1998)
opioid agonist <pharmacology> Any morphine-like compound that produces bodily effects including pain relief, sedation, constipation and respiratory depression.
(16 Dec 1997)
opioid partial agonist <pharmacology> A compound that has an affinity for and stimulates physiologic activity at the same cell receptors as opioid agonists but that produces only a partial (i.e., submaximal) bodily response.
(16 Dec 1997)
LH and RH agonist <pharmacology> Particular medications that act as potent inhibitors of gonadotrophin (testosterone) secretion. They act to inhibit the production of testosterone through a feedback mechanism on the pituitary gland. LH and RH agonists are useful in the treatment of prostate cancer.
(14 Oct 1997)
gated ion channel <physiology> Transmembrane proteins of excitable cells, that allow a flux of ions to pass only under defined circumstances. Channels may be either voltage gated, such as the sodium channel of neurons or ligand gated such as the acetylcholine receptor of cholinergic synapses. Channels tend to be relatively ion specific and allow fluxes of typically 1000 ions to pass in around 1ms, they are thus much faster at moving ions across a membrane than transport ATPases.
(05 May 1997)
voltage-gated channel A class of ion channel's that open and close in response to change in the electrical potential across the plasma membrane of the cell; voltage-gated Na+ c.'s are important for conducting action potential along nerve cell processes.
(05 Mar 2000)
voltage gated ion channel <physiology> A transmembrane ion channel whose permeability to ions is extremely sensitive to the transmembrane potential difference. These channels are essential for neuronal signal transmission and for intracellular signal transduction.
See: sodium channel.
(18 Nov 1997)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Calcium Channel Agonists - »õâ Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture.
    Synonyms : Calcium Channel Agonist, Exogenous Calcium Channel Agonists, Activators, Calcium Channel, Agonist, Calcium Channel, Agonists, Calcium Channel, Channel Activators, Calcium, Channel Agonist, Calcium, Channel Agonists, Calcium
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agonist
    ½Î¿ò(°æ±â)ÀÇ °¡´ãÀÚ;(¹®ÇÐ ÀÛǰÀÇ)ÁÖÀΰø;ÁÖµ¿(ÀÛµ¿)±Ù;ÀÛ¿ë(ÀÛµ¿)¾à(¹°Áú)
  • calcium
    Ä®½·
  • calcium
    Ä®½·(±Ý¼Ó¿ø¼Ò,±âÈ£ Ca,¹øÈ£ 20)
  • calcium arsenate
    ºñ»êÄ®½·(»ìÃæÁ¦)
  • calcium carbide
    źȭĮ½·
  • calcium carbonate
    ź»êÄ®½·
  • calcium chloride
    ¿°È­Ä®½·
  • calcium hydroxide
    ¼ö»êÈ­Ä®½·;¼Ò¼®È¸
  • calcium light
    Ä®½·±¤(limelight)
  • calcium oxide
    »êÈ­Ä®½·;»ý¼®È¸
  • calcium phosphate
    ÀλêÄ®½·
  • channel
    ¼ö·Î
  • Channel Islands
    ÇØÇùÁ¦µµ(ÇÁ¶û½º ºÏ¼­ºÎÀÇ ¿µ·ÉÀÇ ¼¶)
  • English Channel
    ¿µ±¹ ÇØÇù
  • North Channel
    ³ë½º ÇØÇùÄÚÆ²·£µå¿Í ºÏ¾ÆÀÏ·£µå »çÀÌ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á